Filing Flows › Vir Biotechnology (VIR) › Q2 2025
Vir Biotechnology (VIR) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Vir Biotechnology (VIR) reported revenue of $1.2M for the second quarter 2025 (Q2 2025), -61% from a year earlier and -60% from the quarter before.
Vir Biotechnology, Q2 2025: revenue $1.2M (-60% year over year), net loss $111M, operating cash flow −$120M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | -60% | -61% |
| Operating profit | −$118M | — | — |
| Net earnings | −$111M | — | — |
| Operating cash flow | −$120M | — | — |
What changed
Revenue was $1.2M in Q2 2025, down 61% year over year and down 60% from the previous quarter.
Operating costs exceeded revenue by $118.4M, an operating margin of -9754.3%. Total costs fell 26% while revenue fell 61%. The quarter ended with a net loss of $111.0M, narrower than the previous quarter's $121.0M loss.
Operating cash flow was −$120.2M. Non-cash charges added back $2.9M of depreciation and amortization and $12.5M of share-based compensation. Working capital and other items used $24.6M. Capital expenditures of $2.5M exceeded it, leaving free cash flow of −$122.8M.
Questions
What was Vir Biotechnology's revenue in the second quarter 2025?
Vir Biotechnology (VIR) reported revenue of $1.2M for the second quarter 2025 (Q2 2025), -61% from a year earlier and -60% from the quarter before.
Source: Vir Biotechnology 10-Q on SEC EDGAR.